Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND,...
-
Fifth Phase II trial of UV1 in cancer, and largest disease category to dateUV1 will be investigated in combination with the standard-of-care pembrolizumabExpected data read-out by end of 2024 OSLO,...
-
UV1 as add-on therapy to checkpoint inhibitors awarded Fast Track designationProvides for potentially expedited review of UV1Ultimovacs to host webcast at 13.00 CET Thursday, 21 October 2021 OSLO,...
-
OSLO, Norway, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced continuing positive topline...
-
First patient in second cohort dosed with 400 μg of TET vaccineDSMB found no safety concerns for first cohort of three patients at 40 μg dose OSLO, Norway, Oct. 01, 2021 (GLOBE NEWSWIRE) --...
-
OSLO, Norway, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its second quarter 2021 results...
-
Cohort 2 showed 60% objective response rate, 30% complete response rate90% overall survival rate at 12 months follow-upCohort 2 results reinforce results seen in cohort 1Good safety and tolerability...
-
OSLO, Norway, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, invites to a webcast presentation of its...
-
Study will assess the benefit of combining UV1 with standard of care pembrolizumabTopline data expected in 2023 OSLO, Norway, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE...
-
OSLO, Norway, July 05, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication of a...